Retatrutide Reconstitution Calculator

Clinical Pharmacology & Mechanism of Action

Retatrutide (LY3437943) is currently the pinnacle of incretin-based metabolic engineering. While Semaglutide is a single agonist (GLP-1) and Tirzepatide is a dual agonist (GIP/GLP-1), Retatrutide is a first-in-class Triple Hormone Receptor Agonist.

It binds to and activates the GLP-1, GIP, and Glucagon receptors simultaneously.

This tri-agonist approach yields unparalleled metabolic effects, primarily due to the addition of glucagon receptor agonism:

• GLP-1 & GIP: Suppress appetite centrally, slow gastric emptying, and improve insulin sensitivity (similar to Tirzepatide).
• Glucagon Agonism: Unlike GLP-1 and GIP, glucagon agonism directly stimulates hepatic glucose production and dramatically increases baseline energy expenditure. It essentially forces the body to burn more calories at rest while accelerating lipid mobilization and lipolysis (fat burning) in the liver .

The combination of extreme appetite suppression (restricting calories in) with glucagon-mediated metabolic rate increases (burning more calories out) results in unprecedented weight loss data in Phase 2 trials.

Pharmacokinetics & Half-Life

Retatrutide is engineered for once-weekly administration via a similar fatty-acid moiety attachment seen in earlier incretins.

• Half-life: Approximately 6 days.
• Steady State: Due to the 6-day half-life, it requires roughly 4 weeks of consistent dosing for the peptide to fully accumulate to a stable plasma concentration.

Standard Research Dosing Protocols (Titration)

Because of the addition of glucagon agonism, Retatrutide requires a careful titration schedule. In clinical trials, rapid dose escalation led to issues with cardiac arrhythmias (increased resting heart rate) and gastrointestinal distress.

The phase 2 trial standard titration schedule is:

1. Weeks 1 - 4 (Initiation): 2.0mg once weekly.
2. Weeks 5 - 8: 4.0mg once weekly.
3. Weeks 9 - 12: 6.0mg once weekly.
4. Weeks 13 - 16: 9.0mg once weekly.
5. Weeks 17+ (Maintenance): 12.0mg once weekly.

Note: The maximum dose is 12.0mg, though many subjects achieve profound 20%+ weight loss staying at 4.0mg or 6.0mg.

Reconstitution Math & Syringe Guide

Retatrutide research vials are typically sold in 10mg, 20mg, or 30mg increments due to the higher dosing requirements.

Step-by-Step Reconstitution (10mg Vial)

1. Swab the rubber stoppers of your 10mg Retatrutide vial and your Bacteriostatic Water.
2. Using a sterile mixing syringe, draw exactly 2mL of Bacteriostatic Water.
3. Inject the water slowly down the inside wall of the Retatrutide vial.
4. Swirl gently. Wait for the solution to become clear.

The Math for an Initiation Dose (2.0mg):

• 10mg total in the vial.
• You added 2mL of water.
• Therefore, the concentration is 5mg per 1mL.
• You need a 2.0mg dose. Divide the dose by the concentration: 2.0 ÷ 5 = 0.4mL.
• 0.4mL = 40 units on a U-100 syringe.

Common Mistakes & Troubleshooting

• Monitoring Heart Rate: A known physiological effect of glucagon agonism is a slight increase in resting heart rate. Researchers must monitor subjects for tachycardia, especially during the first few weeks of dose escalation.
• Under-hydration: Glucagon agonism increases metabolic rate and water turnover. Failing to aggressively hydrate can lead to severe headaches, cramping, and lethargy.
• Dosing Errors with 30mg Vials: When using highly concentrated 30mg vials, adding only 2mL of water yields a very dense 15mg/mL solution. A 2.0mg dose would then be extremely small (0.13mL or 13 units). Always double-check math when moving to larger vials.